Compare Stocks: ZNTL, ARDX, IVA, and COLL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.89	$5.05	$3.86 ▼ $8.40	$969.35M	0.7	4.90 million shs	2.88 million shs
COLL Collegium Pharmaceutical	$27.11	$33.67	$25.47 ▼ $50.79	$882.59M	0.73	755,205 shs	704,930 shs
IVA Inventiva	$4.68	$4.27	$3.35 ▼ $7.98	$972.08M	0.7	688,336 shs	461,396 shs
ZNTL Zentalis Pharmaceuticals	$3.83	$4.35	$1.21 ▼ $6.95	$274.50M	1.92	1.17 million shs	740,757 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	0.00%	-4.19%	-22.66%	-36.33%	-36.33%
COLL Collegium Pharmaceutical	0.00%	-3.97%	-22.98%	-20.43%	-30.68%
IVA Inventiva	0.00%	+1.74%	+4.93%	-7.69%	+4.70%
ZNTL Zentalis Pharmaceuticals	0.00%	+7.58%	-11.55%	-5.67%	+92.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.89	$5.05	$3.86 ▼ $8.40	$969.35M	0.7	4.90 million shs	2.88 million shs
COLL Collegium Pharmaceutical	$27.11	$33.67	$25.47 ▼ $50.79	$882.59M	0.73	755,205 shs	704,930 shs
IVA Inventiva	$4.68	$4.27	$3.35 ▼ $7.98	$972.08M	0.7	688,336 shs	461,396 shs
ZNTL Zentalis Pharmaceuticals	$3.83	$4.35	$1.21 ▼ $6.95	$274.50M	1.92	1.17 million shs	740,757 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	0.00%	-4.19%	-22.66%	-36.33%	-36.33%
COLL Collegium Pharmaceutical	0.00%	-3.97%	-22.98%	-20.43%	-30.68%
IVA Inventiva	0.00%	+1.74%	+4.93%	-7.69%	+4.70%
ZNTL Zentalis Pharmaceuticals	0.00%	+7.58%	-11.55%	-5.67%	+92.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.75	Moderate Buy	$13.90	257.33% Upside
COLL Collegium Pharmaceutical	2.71	Moderate Buy	$51.00	88.12% Upside
IVA Inventiva	3.09	Buy	$16.56	253.75% Upside
ZNTL Zentalis Pharmaceuticals	2.33	Hold	$6.75	76.24% Upside

Current Analyst Ratings Breakdown

Latest ZNTL, ARDX, IVA, and COLL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	COLL Collegium Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$56.00 ➝ $48.00
8/18/2026	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$9.00
8/17/2026	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$16.00 ➝ $15.00
8/11/2026	COLL Collegium Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/10/2026	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $11.00
8/7/2026	ARDX Ardelyx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $10.00
8/7/2026	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/7/2026	ARDX Ardelyx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00 ➝ $14.00
8/7/2026	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$45.00 ➝ $43.00
8/6/2026	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$56.00 ➝ $46.00
7/28/2026	COLL Collegium Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$407.32M	2.38	N/A	N/A	$0.69 per share	5.64
COLL Collegium Pharmaceutical	$808.21M	1.09	$15.23 per share	1.78	$9.54 per share	2.84
IVA Inventiva	$5.07M	191.73	N/A	N/A	($0.22) per share	-21.27
ZNTL Zentalis Pharmaceuticals	$67.43M	4.07	N/A	N/A	$2.99 per share	1.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$61.60M	-$0.22	N/A	16.21	N/A	-12.35%	-36.00%	-10.77%	10/29/2026 (Estimated)
COLL Collegium Pharmaceutical	$62.87M	$1.24	21.86	4.80	N/A	5.93%	91.43%	15.57%	11/5/2026 (Estimated)
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2026 (Estimated)
ZNTL Zentalis Pharmaceuticals	-$137.06M	-$1.95	N/A	N/A	N/A	N/A	-70.18%	-51.46%	11/9/2026 (Estimated)

Latest ZNTL, ARDX, IVA, and COLL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
8/6/2026	Q2 2026	COLL Collegium Pharmaceutical	$1.72	$1.92	+$0.20	-$0.46	$199.63 million	$199.88 million
8/6/2026	Q2 2026	ZNTL Zentalis Pharmaceuticals	-$0.49	-$0.59	-$0.10	-$0.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
ZNTL Zentalis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.69	3.34	3.15
COLL Collegium Pharmaceutical	3.32	1.03	0.84
IVA Inventiva	N/A	3.16	3.16
ZNTL Zentalis Pharmaceuticals	N/A	4.82	4.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
COLL Collegium Pharmaceutical	N/A
IVA Inventiva	19.06%
ZNTL Zentalis Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.30%
COLL Collegium Pharmaceutical	1.85%
IVA Inventiva	32.00%
ZNTL Zentalis Pharmaceuticals	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	249.19 million	235.98 million	Optionable
COLL Collegium Pharmaceutical	210	32.56 million	31.95 million	Optionable
IVA Inventiva	100	207.71 million	141.24 million	Not Optionable
ZNTL Zentalis Pharmaceuticals	160	71.67 million	68.95 million	Optionable

ZNTL, ARDX, IVA, and COLL Headlines

Recent News About These Companies

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Acquires 4,335,000 Shares

August 20, 2026 | insidertrades.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock

August 19, 2026 | marketbeat.com

Zentalis Pharma closes $92.6 million public offering

August 19, 2026 | thepharmaletter.comT

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

August 17, 2026 | markets.businessinsider.com

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

August 17, 2026 | globenewswire.com

GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL

August 17, 2026 | marketbeat.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Hold" by Analysts

August 16, 2026 | americanbankingnews.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages

August 16, 2026 | marketbeat.com

Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline

August 14, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals slides after pricing 23M share public offering at $3.50/share

August 14, 2026 | msn.com

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

August 13, 2026 | globenewswire.com

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

August 13, 2026 | globenewswire.com

HC Wainwright Analysts Decrease Earnings Estimates for ZNTL

August 11, 2026 | marketbeat.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen

August 8, 2026 | marketbeat.com

Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL

August 7, 2026 | marketbeat.com

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

August 6, 2026 | finance.yahoo.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

August 6, 2026 | marketbeat.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Zentalis Pharmaceuticals (ZNTL) Expected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

July 20, 2026 | zacks.com

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

July 17, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZNTL, ARDX, IVA, and COLL Company Descriptions

Ardelyx NASDAQ:ARDX

$3.89 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Collegium Pharmaceutical NASDAQ:COLL

$27.11 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Inventiva NASDAQ:IVA

$4.68 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Zentalis Pharmaceuticals NASDAQ:ZNTL

$3.83 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZNTL, ARDX, IVA, and COLL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZNTL, ARDX, IVA, and COLL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZNTL, ARDX, IVA, and COLL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZNTL, ARDX, IVA, and COLL Company Descriptions

Ardelyx NASDAQ:ARDX

Collegium Pharmaceutical NASDAQ:COLL

Inventiva NASDAQ:IVA

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZNTL, ARDX, IVA, and COLL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZNTL, ARDX, IVA, and COLL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZNTL, ARDX, IVA, and COLL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZNTL, ARDX, IVA, and COLL Company Descriptions

Ardelyx NASDAQ:ARDX

Collegium Pharmaceutical NASDAQ:COLL

Inventiva NASDAQ:IVA

Zentalis Pharmaceuticals NASDAQ:ZNTL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools